-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $105

Benzinga·02/25/2026 17:44:54
Listen to the news
Oppenheimer analyst Francois Brisebois maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and raises the price target from $95 to $105.